While there has been quite a number of IPOs getting listed on SGX recently, none have managed to successfully capture my attention, but I was admittedly quite intrigued when SGX informed me that there was a new healthcare IPO coming to the Catalist Board.


Clearbridge Health Limited commenced trading today. Its IPO price was at $0.28, which unfortunately was not open to public subscription, and it ended its first day of trading flat at the same price.


Clearbridge specialises in precision medicine, which is the practice of identifying the individual characteristics of each patient as well as probability of diseases, based on their genomic and metabolomics profile. 
They also offer Clinical diagnostic tests through their in-house laboratory, SAM Laboratory Pte Ltd, which includes:
– Health screening 
– Cancer diagnosis  
– Biomarker diagnostics, capable of surveying for over 138 possible conditions
– Treatment monitoring and prognosis